Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.

Abstract

Drug resistance remains a major obstacle to successful cancer treatment. A database of drug-associated gene expression profiles was screened for molecules whose profile overlapped with a gene expression signature of glucocorticoid (GC) sensitivity/resistance in acute lymphoblastic leukemia (ALL) cells. The screen indicated that the mTOR inhibitor rapamycin profile matched the signature of GC sensitivity. We tested the hypothesis that rapamycin would induce GC sensitivity in lymphoid malignancy cells and found that it sensitized to GC-induced apoptosis via modulation of antiapoptotic MCL1. These data indicate that MCL1 is an important regulator of GC-induced apoptosis and that the combination of rapamycin and glucocorticoids has potential utility in lymphoid malignancies. Furthermore, this approach represents a strategy for identification of promising combination therapies for cancer.

010020030020072008200920102011201220132014201520162017
Citations per Year

2,247 Citations

Semantic Scholar estimates that this publication has 2,247 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Wei2006GeneEC, title={Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.}, author={Guo Wei and David Twomey and Justin Lamb and Krysta D Schlis and Jyoti Agarwal and Ronald W. Stam and Joseph T. Opferman and Stephen E. Sallan and Monique L den Boer and Rob Pieters and Todd R. Golub and Scott A. Armstrong}, journal={Cancer cell}, year={2006}, volume={10 4}, pages={331-42} }